Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. - Wikidata - wikimedia - TriplyDB

Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases.

Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases.

http://www.wikidata.org/entity/Q34005870

about

Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.The clinicopathologic importance of serum lactic dehydrogenase in patients with gastric cancer Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer.The clinical implication of cancer-associated microvasculature and fibroblast in advanced colorectal cancer patients with synchronous or metachronous metastases Clinical features and prognosis in hepatectomy for colorectal cancer with centrally located liver metastasis.Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis.Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer.An overview of colorectal cancer survival rates and prognosis in Asia Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice.The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis.The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study.Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.KRAS mutation in lung metastases from colorectal cancer: prognostic implications.Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial Limited effect of lymph node status on the metastatic pattern in colorectal cancer Young patients with synchronous colorectal liver metastases.The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review.Management of colorectal cancer presenting with synchronous liver metastases.The association between clinical outcome and CD8+ lymphocytic infiltration in advanced stages of colorectal cancer differs by latent virus infection in the tumour tissue.Oligometastatic Disease in the Peritoneal Space with Gastrointestinal Cancer.I BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 2: APPROACH TO RESECTABLE METASTASES.Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway.Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy.Synchronous vs. Metachronous Metastases in Adrenocortical Carcinoma: an Analysis of the Dutch Adrenal Network.Liver Resection for Non-colorectal Non-neuroendocrine Metastases: Where Do We Stand Today Compared to Colorectal Cancer?Aberrant expression of long noncoding RNAs in colorectal cancer with liver metastasis.Growth pattern of colorectal liver metastasis as a marker of recurrence risk.Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer.Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo.Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?

P2860

Q33611481-5AD55D35-0CA6-450F-A615-5F86E73FA7A0 Q34371471-94AAEFA1-3FB3-4185-B204-4E62C132A42F Q34534959-44F14017-2A0D-4DFC-99EC-615BAB135B5D Q34766068-B34957FA-1969-4781-9B6C-7E6F42930ADA Q35124011-1650F9D8-8DDA-42A3-9216-961DA0C1A693 Q35162606-913A71F9-E631-4C6C-8C9F-438711CFE80D Q35191219-17D81E89-8090-4E99-8113-1A951B2ED1EB Q35632071-CE73B28F-81A1-4448-8871-BC4284C31DCB Q35906947-70FAA189-BD91-4D5F-B061-9D0BF871C821 Q35925226-9CE204BA-C9DD-4225-8ACE-D219BB2FDA62 Q35970714-39E0C1D9-2CE8-43F6-9BFA-E011A95D5BCF Q36405660-2BB913CB-B36D-4A1B-AF0A-72817A668FC6 Q36444723-54477C9A-ACE6-4527-8A89-717C8FB2D058 Q36528345-F2C81CB6-74AB-4C9D-B236-CBF3B9200DC9 Q37182219-DFFA30FC-F628-4902-8495-D7C3B43890E9 Q37362497-BA41AAED-04A1-471D-95E6-E4616E82F48A Q37445913-DF953114-70DD-43D6-837D-F5C7E79DA74C Q38062470-181E598B-6144-4445-A7F6-C7204D3472B7 Q38217004-B35837B0-A0F7-41AC-B84C-40ED1D58065D Q38651457-BE97978F-0664-406F-9ECF-86A5F44E6170 Q38726776-023ED2EC-25C8-4CFA-90DB-83D2CF8A5F22 Q38819105-59CF78C4-C0E6-4B28-B9FE-7F639DBF2C70 Q38970211-C0C837F6-78D9-486C-869C-E38687CB8A90 Q39246331-FFA024D4-AE54-4506-9AAF-044562C046AD Q39596712-F46EC8B3-5DB0-42EB-AA3A-3C1D6B55C2F4 Q39964506-0385FB8D-BDF0-41A6-8FD3-08CEC84770D3 Q40862468-63931651-22B4-45E3-93DF-882D29DA87BC Q41140410-E24CB5DC-B0C6-442E-9DC7-B43B0BD528CF Q45852233-BDD10874-5123-4C2D-A3A6-ADE39E5480EA Q47418694-D47DB5A6-D487-4890-A3A6-BAC14456587E Q48165994-392239B1-A98B-460C-9CEC-987E16A3B4DC Q49737539-346F26F1-427A-4759-88D8-6338FCE2009B Q51084286-0728CB89-9570-427A-8F97-95A2AF4BB8FF Q53213677-6BE097A3-A2C8-488A-81D2-F7D46F596829

P2860

Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases.

http://www.wikidata.org/entity/Q34005870

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Clinicopathological features a ...... us vs metachronous metastases.

@ast

Clinicopathological features a ...... us vs metachronous metastases.

@en

Clinicopathological features a ...... us vs metachronous metastases.

@nl

type

label

Clinicopathological features a ...... us vs metachronous metastases.

@ast

Clinicopathological features a ...... us vs metachronous metastases.

@en

Clinicopathological features a ...... us vs metachronous metastases.

@nl

prefLabel

Clinicopathological features a ...... us vs metachronous metastases.

@ast

Clinicopathological features a ...... us vs metachronous metastases.

@en

Clinicopathological features a ...... us vs metachronous metastases.

@nl

P1433

Q34005870-0982A033-3F03-40A7-8EC2-55ABFB4133B1

P1476

Q34005870-7B30F56E-6D66-4630-84AE-9C8A3A814F38

P2093

Q34005870-53A9A291-362C-46BC-920E-DDE5AB2CA844

Q34005870-54D6CD35-104E-4D47-AEC7-7FFFD2183731

Q34005870-5F3E3EE8-7B5D-4B19-91F5-42ED8552700B

Q34005870-641DA515-0D73-4C95-B477-0FA603C5C932

Q34005870-8ED0798E-8898-4680-AA08-851E03AE3ED6

P2860

Q34005870-0887BA2E-F4CD-425E-AF2E-530BC0A04329

Q34005870-1433B0C3-2D22-4287-BE34-FD7BA040ACE7

Q34005870-2406E966-026A-4DE2-9D63-6F83C64B3E53

Q34005870-27BE04E6-FAEB-4BCC-BD13-68A171E65FBF

Q34005870-2CBE07A4-33F4-4A31-BDC8-1AC935AD0240

Q34005870-2F993A2D-BA67-4260-8B3C-FB0A509DBF15

Q34005870-351AA777-DA3B-458D-981A-47A23D237CA2

Q34005870-3CBA0609-3D7F-4914-9C5A-A39AB34C01D4

Q34005870-60063334-33D0-4C04-832D-82B2FD17731F

Q34005870-63A962EB-D2BB-43BC-A012-2B59EAF0FAE0

P2888

Q34005870-6F2172FD-B08B-48E3-94F3-1F283760350B

P304

Q34005870-D54CB6C6-075E-4253-B107-1A9A4DB8EB3D

P31

Q34005870-39600B4A-8933-48B1-B0E2-CB31287D993A

P356

Q34005870-B7CA32FD-464F-4466-A947-211F84D81465

P407

Q34005870-850217B9-BCA8-43B1-AF11-7D95D40FF487

P433

Q34005870-1CB4D795-CE5D-4A16-B619-84F975366E4A

P478

Q34005870-3080CDB0-1E17-4550-AE6E-C0D7A0190A3F

P50

Q34005870-10435535-F473-4B6B-B9CE-CEE16124F1CA

Q34005870-3525B825-1910-4C57-8ADF-DCC43C26730B

P577

Q34005870-ECE50004-5F3B-4419-8BDB-52A2BC267E6F

P5875

Q34005870-E923D5FA-0281-4222-8714-389A968D1AB5

P6179

Q34005870-8321A233-A085-4395-928B-81D8B61E5304

P698

Q34005870-7783BEAB-A335-48E7-B330-B035D9CC833A

P921

Q34005870-220249E0-E58E-4A1C-AA5E-97147EC0AC9F

P932

Q34005870-A46B370A-8293-4166-ACDE-ABFBBD9F28E1

P356

P1433

British Journal of Cancer

P1476

Clinicopathological features a ...... ous vs metachronous metastases

@en

P2093

C J A Punt

http://www.w3.org/2001/XMLSchema#string

J H J M van Krieken

http://www.w3.org/2001/XMLSchema#string

L J M Mekenkamp

http://www.w3.org/2001/XMLSchema#string

M Koopman

http://www.w3.org/2001/XMLSchema#string

S Teerenstra

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.

'Staged' liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

ABC of colorectal cancer: effectiveness of follow up.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.

Predictors of survival after hepatic resection among patients with colorectal liver metastasis.

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.

P2888

P304

159-164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605737

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44676928

http://www.w3.org/2001/XMLSchema#string

P6179

1007147470

http://www.w3.org/2001/XMLSchema#string

P698

20551951

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

2906733

http://www.w3.org/2001/XMLSchema#string